This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Johnson & Johnson

Drug Names(s): GSK2336805, GSK805, JNJ56914845

Description: GSK2336805 is a hepatitis C virus NS5A inhibitor.

Deal Structure: GSK2336805 was originally developed by GlaxoSmithKline.

GSK and Janssen (JNJ)
In October 2013, Medivir announced that Janssen has acquired the compound GSK2336805 (GSK805) in development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GlaxoSmithKline, financial details of the agreement have not been disclosed.

JNJ-56914845 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug